home / stock / artl / artl news

ARTL News and Press, Artelo Biosciences Inc. From 04/13/22

Stock Information
Company Name: Artelo Biosciences Inc.
Stock Symbol: ARTL
Market: OTC
Website: artelobio.com
Menu
ARTL ARTL Quote ARTL Short ARTL News ARTL Articles ARTL Message Board
Get ARTL Alerts

News, Short Squeeze, Breakout and More Instantly...
ARTL - Artelo Biosciences stock soars 40% on pre-clinical data for ART27.13 in cancer-related muscle degeneration

Artelo Biosciences (NASDAQ:ARTL) said ART27.13 has shown promising pre-clinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia) via a CB2 mediated mechanism of action. The company said ART27.13, a peripherally selective G-Protein Coupled Receptor (G...
ARTL - Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia

SOLANA BEACH, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, ...

ARTL - Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer

SOLANA BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced...

ARTL - Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced it has been invited to...
ARTL - Artelo Biosciences GAAP EPS of -$0.12

Artelo Biosciences press release (NASDAQ:ARTL): 4M GAAP EPS of -$0.12. As of December 31, 2021, the Company had approximately $25.6 million in cash and investments, compared to $10.1 million as of December 31, 2020. The reporting of this four-month period and the concurrent filing of its Form...

ARTL - Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update

SOLANA BEACH, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and opera...

ARTL - Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for a...
ARTL - Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol

SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced...

ARTL - Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update

Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30, 2021 SOLANA BEACH, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ...

ARTL - Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom

SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical cannabinoid, ART27.13 , as “non-controlled” and, therefore, is no lo...
Previous 10 Next 10